NCT07039474
The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
Recruiting · Not specified · Peking University First Hospital · registry updated 2026-09-28
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The purpose of this study is to explore the effectiveness of 18F-G1 PET/CT in patients with solid tumors and hematological malignancies receiving immunotherapy
Inclusion
- Subjects diagnosed with a malignant tumor by histopathology who are going to receive immunotherapy (monotherapy or combined immunotherapy) recommended by the multidisciplinary team.
- Subjects didn't receive previous immunotherapy.
- There exists at least one measurable target lesion according to the RECIST 1.1.
- ECOG performance status≤2.
- The expected survival time is ≥6 months.
- Effective contraceptive measures will be adopted during the study period and within 6 months after the study.
Exclusion
- Women in the preconception period, pregnancy, or lactation period.
- Combined with other malignant tumor.
- Diagnosed with autoimmune disease, or have long history of systemic steroid hormone therapy or immunosuppressive therapy.
- Having a history of severe cardiovascular disease, severe hepatic and renal insufficiency.
- Receiving radiotherapy or interventional therapy during the immunotherapy.
- F-G1 PET/CT or 18F-FDG PET/CT is not performed in our department, or the interval between baseline imaging and immunotherapy is more than 30 days.